Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-09
2007-01-09
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S317000, C514S408000, C514S562000, C514S649000
Reexamination Certificate
active
10104709
ABSTRACT:
Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5374548 (1994-12-01), Caras
patent: 5399331 (1995-03-01), Kasai et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5444095 (1995-08-01), Tatton et al.
patent: 6417160 (2002-07-01), Tatton et al.
patent: WO 92/17169 (1992-10-01), None
patent: WO 9325219 (1993-12-01), None
patent: WO 97/28791 (1997-08-01), None
patent: WO 97/33572 (1997-09-01), None
Apfel, et al. (1993)The Use of Insulin-Like Growth Factor I in the Prevention of Vincristine Neuropathy in Mice,AN. N. Y. ACAD. SCI.,692:243-245.
Berge, S.M. et al. “Pharmaceutical Salts”Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
Bernheimer, H. et al. “Brain Dopamine and the Syndromes of Parkinson and Huntington Clinical, Morphological and Neurochemical Correlations”Journal of the Neurological Sciences 20:415-455 (1973).
Birkmayer, W. et al. “(-)-Deprenyl Leads to Prolongation ofL-Dopa Efficacy in Parkinson's Disease”Mod. Probl. Pharmacopsychiat. 19:170-176 (1983).
Birkmayer, W. and Riederer, P. “Deprenyl Prolongs the Therapeutic Efficacy of Combined L-DOPA in Parkinson's Disease”Advances in Neurology 40:475-481 (1984).
Birkmayer, W. et al. “Increased Life Expectancy Resulting from Addition of L-Depmyl to Madopar® Treatment in Parkinson's Disease: A Longterm Study”Journal of Neural Transmission 64:113-127 (1985).
Birkmayer, W. et al. “The Potentiation of the Anti Akinetic Effect after L-Dopa Treatment by and Inhibitor of Mao-B, Deprenil”Journal of Neural Transmission 36:303-326 (1975).
Bloemen, P.G.M. et al. “Adhesion Molecules: A New Target for Immunoliposome-mediated Drug Delivery”FEBS Letters 357:140-144 (1995).
Briscoe, P. et al. “Delivery of Superoxide Dismutase to Pulmonary Epithelium via pH-Sensitive Liposimes”Am. J. Physiol. 268:L374-L380 (1995).
Cedarbaum, J.M. et al. “A Double-blind Crossover Comparison of Sinemet CR4 and Standard Sinemet 25/100 in Patients with Parkinson's Disease and Fluctuating Motor Performance”Journal of Neurology, Neurosurgery, and Psychiatry 52:207-212 (1989).
Conn's current therapy, Rankel, R.E. Editor, W.B. Sauders Company, A Division of Harcourt Brace & Company Philadelphia, USA pp. 489-490 (1989).
Elizan, T.S. et al. “Selegiline as and Adjunct to Conventional Levodopa Therapy in Parkinson's Disease”Arch. Neurol. 46:1280-1283 (1989).
Fischer, P.-A. and Baas, H. “Therapeutic Efficacy of R-(—)-deprenyl as Adjuvant Therapy in Advanced Therapy in Advanced Parkinsonism”J. Neural. Transm. 25(Suppl.):137-147 (1987).
Golbe, L.I. “Long-term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease”Neurology 39:1109-1111 (1989).
Golbe, L.I. et al. “Selegiline and Parkinson's Disease—Protective and Symptomatic Considerations”Drugs 39(5):646-651 (1990).
Ishii, D.N., et al. (1995)“Insulin-Like Growth Factors Protect Against Diabetic Neuropathy: Effects on Sensory Nerve Regeneration in Rats”, Journal of Neurosciece Rsearch, 40(1):138-144.
Keinänen and Laukkanen, M-L. “Biosynthetic Lipid-tagging of Antibodies”FEBS Letters 346:123-126 (1994).
Killion, J.J. and Fidler, I.J. “Systemic Targeting of Liposome-Encapsulated Immunomodulators to Macrophages for Treatment of Cancer Metastasis”Immunomethods 4:273-279 (1994).
Lieberman, A.N. et al. “Deprenyl Versus Placebo in Parkinson Disease: A Double-blind Study”New York State Journal of Medicine 87:646-649 (1987).
Love, et. al. (1996)“Effects of the sulfhydryl donor NAC on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats”,European Journal of Clinical investigation, 26(8):698-706.
Morgenlander, J.C. “Recognizing Peripheral Neuropathy—How to Read the Clues to an Underlying Cause”Postgraduate Medicine 102(3):71-80 (1997).
Owais, M. et al. “Chloroquine Encapsulated in Malaria-Infected Eryghrocyte-Specific Antibody-Bearing Liposomes Effectively Controls Chloroquine-ResistantPlasmodium bergheiInfections in Mice”Antimicrobial Agents and Chemotherapy 39(1); 180-184 (1995).
Parkinson Study Group “DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease”Arch. Neurol. 46:1052-1060 (1989).
The Parkinson Study Group “Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease”New England Journal of Medicine 321:1364-1371 (1989).
Ranade, V.V. “Drug Delivery Systems. 1. Site-Specific Drug Delivery Using Liposomes as Carriers”J. Clin. Pharmacol. 29:685-694 (1989).
Rideout, et al. (1997)“High Glucose Induced Apoptosis Of Schwann Cells Is Prevented By IGF-1 and (-) Desmehydeprenyl”,Soc. for Neurosci. Abstr.,23(1-2): 65.
Sagara, et al. (1996)“Inhibition of peripheral neuropathy in streptoxotocin-induced diabetic rats with NAC”,Diabetologia, 39(3):263-269.
Schiller, J.H. et al. “Amifostine, Cisplatin, and Vinblastine in Metastatic Non-Small-Cell Lung Cancer: A Report of High Response Rates and Prolonged Survival”Journal of Clinical Obcology 14(6):1913-1921 (1996).
Schreier, H. et al. “Targeting of Liposomes to Cells Expressing CD4 Using Glycosylphosphatidylinositol-anchored gp120”The Journal of Biological Chemistry 269(12):9090-9098 (1994).
Sondell, et. al. (1997)The IGF I In The Prevention Of Vincristine,Neuroreport, 8(13):2871-2876.
Stedman's medical dictionary, 26thed. Williams & Wilkins, a Waverly Co. p. 305(1995).
Tabernero, A., et al. (1996)“IGFs Exert a Positive Effect On Both the Proliferation and Differentiotion of Rat Schwann cells in culture”,Journal of Physiology, 493:162s.
Umezawa, F. and Eto, Y. “Liposome Targeting to Mouse Brain: Mannose as a Recognition Marker”Biochemical and Biophysical Research Communications 153(3):1038-1044 (1988).
Veldhuis, G.J. et al. “Paclitaxel, Ifosfamide and Cisplatin with Granulocyte Colony-stimulating Factor or Recombinant Human Interleukin 3 and Granulocyte Colony-stimulating Factor in Ovarian Cancer: A Feasibility Study”British Journal of Cancer 75(5):703-709 (1997).
Zhuang, et al. (1996)“IGFs Reverse or Arrest Diabetic Neuropathy”,Experimental Neurology, 140:198-205.
Tatton Nadine A.
Tatton William G.
Chism B. Dell
Hanley, Esq. Elizabeth A.
Lahive and Cockfield, LLP
Soroos, Esq. Cynthia M.
LandOfFree
Methods for increasing schwann cell survival does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for increasing schwann cell survival, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for increasing schwann cell survival will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806113